DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR THE DETERMINATION OF ATENOLOL AND HYDROCHLORTHIAZIDE IN COMBINED SOLID DOSAGE FORM
Objective: To develop a simple, selective and rapid stability indicating reversed phase high performance liquid chromatographic (HPLC) method for the analysis of Atenolol and hydrochlorothiazide in combined in combined pharmaceutical dosage form as per ICH guidelines.
Methods: The separation was achieved from C18 column at 25oc with a mobile phase consisting of methanol: phosphate buffer in the ratio of 70:30 v/v with a flow rate of 0.5 ml/min (UV detection at 226 nm) and the retention time was about 2.3 min for Atenolol and 2.9 for hydrochlorothiazide. This method was selective to Atenolol and hydrochlorothiazide and also describes the analysis of degraded products of Atenolol and hydrochlorothiazide.
Results: ATN and HCZ were found to be linear in the concentration range of 20 â€“ 100 Âµg/ml and 10 â€“ 50 Âµg/ml respectively. Amount of ATN and HCZ were found in the range from 99.14 â€“ 101.56% and 95.44 â€“ 99.80% respectively. The amounts of degradation products for ATN were found to be 9.45% (in acidic condition), 34.9% (in basic condition), 0.15% (in oxidized condition), 4.55% (in thermal condition), 2.65% (in UV degradation at 254 nm) and 2.4% (in UV degradation at 366 nm). The amounts of degradation products for HCTZ were found to be 0.5% (in acidic condition), 8.0% (in basic condition), 8.1% (in thermal condition), 5.5% (in UV degradation at 254 nm) and 4.0% (in UV degradation at 366 nm).
Conclusion: The developed stability indicating assay method was found to be simple, accurate, sensitive, prÃ©cised, specific and rapid. This method can be applied for routine quantitative analysis of Atenolol and hydrochlorothiazide in bulk and pharmaceutical formulation like tablets. This method was also capable to separate the degradation product of both drugs. Hence, it can be used to check the quality of product after different storage conditions and also in stress degradation study.
2. Martindale, Pharmaceutical Press: Edn 34. 2005. p. 865, 933, 947.
3. The Merck Index, Merck & Co., Inc. Edn 14, Whitehouse Station. NJ; 2006. p. 859, 4781, 5583.
4. Prasad CV, Parihar C, Sunil K, Parimoo P. Simultaneous determination of amilorideHCl, hydrochlorothiazide and atenolol in combined formulations by derivative spectroscopy. J Pharm Biomed Anal 1998;17:877-84.
5. Sivakumar T, Venkatesan P, Manavalan R, Valliappan K. Development of a HPLC method for the simultaneous determination of Losartan potassium and Atenolol in tablets. Indian J Pharm Sci 2007;69:154-7.
6. Parthiban C, Bhagavan RM, Sudhakar M. Simultaneous estimation and validation of Atenolol, hydrochlorothiazide and Losartank in dosage form by RP-HPLC method. Int J Pharm Ind 2011;1:4.
7. Nevin E. Spectrophotometric analysis of Hydrochlorothiazide and Valsartan. Anal Lett 2002;35:283-302.
8. Bhushan R, Deepak G, Shravan KS. Liquid chromatographic separation and UV determination of certain antihypertensive agents. Biomed Chromato 2005;20:217-24.
9. Zaveri M, Khandhar A. Development and Validation of a RP-HPLC for the simultaneous estimation of atenolol and hydrochlorothiazide in pharmaceutical dosage forms. Int J Adv Pharm Sci 2010;167-71.